Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke - Comparison of the clinical benefit of statins on the basis of randomised controlled endpoint studies

European Journal of Medical Research

Volumn 9, Issue 1, 2004, Pages 1-17

  Gresser, Ursula ^a   Gathof, B S ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Atorvastatin; Benefit; Coronary Heart Disease; Fuvastatin; HMG CoA reductase inhibitors; Lovastatin; Major coronary event; Pravastatin; Rosuvastatin; Simvastatin

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEART MUSCLE ISCHEMIA; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD;

ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR ACCIDENT; HEPTANOIC ACIDS; HUMANS; MYOCARDIAL ISCHEMIA; PYRROLES; RANDOMIZED CONTROLLED TRIALS;

EID: 1542319758     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Armitage J, Collins R. Need for large scale randomized evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart 84: 357-360, 2000
2. Clifford TJ, Barrowman NJ, Moher D. Founding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res. 2002 Sep 4;2(1):18. Epub 2002 Sep 04
3. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5.963 people with diabetes: a randomized placebo-controlled trial. Lancet 361: 2005-2016, 2003
4. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 56: 53-56, 2002
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM - for the Air Force/Texas Coronary Atherosclerosis Prevention Study Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279: 1615-1622, 1998
6. Gresser U. A living legend of German clinical medicine. Eur J Med Res 8: 47-48, 2003
7. Heart Protection Study Collaborative Grou MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20: 725-741, 1999
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360: 7-22, 2002 - a
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360: 23-33, 2002 - b
10. Liem AH, van Boven AJ, Veeger NJGM, Withagen AJ, Robles de Medina RM, Tijssen JGP, van Veldhuisen DJ - for the Fluvastatin on risk diminishment after acute myocardial infarction (FLORIDA) study group. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 23: 1931-1937, 2002
11. Mamdani MM, Tu JV. Did the major clinical trials of statins affect prescribing behaviour? CMAJ 164: 1695-1696, 2001
12. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyzes? Lancet 352: 609-613, 1998
13. Moher D, Schulz KF, Altmann DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 357: 1191-1194, 2001
14. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 92: 670-676, 2003
15. Nissen SE. REVERSAL. A prospective, randomized, double blind, multicenter study comparing the effects of atorvastatin vs. pravastatin on the progression of coronary atherosclerotic lesions as measured by intravascular ultrasound. American Heart Association Meeting, Scientific Sessions 2003, Plenary Session XI, Late-Breaking Clinical Trials. Orlando, FL 12 Nov 2003
16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E - for the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009, 1996
17. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994
18. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T - for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711-1718, 2001
19. Serruys PWJC, de Feyter P, Macaya C, Kokett N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B - for the Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287: 3215-3222, 2002
20. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J - for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361: 1149-1158, 2003
21. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG - on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360: 1623-1630, 2002
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ - for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307, 1995
23. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357, 1998
24. Waters D. Statins and safety: applying the results of randomized trials to clinical practice. Am Coll Cardiol 92: 692-695, 2003